Full Text
Budget Impact Analysis of Nanoliposomal Irinotecan for Treatment of Pancreatic Cancer Following Progression on Gemcitabine - A Us Payer Perspective

Abstract

Authors

C Becker K Mamlouk H Li

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×